



NDA 20903/S-57
NDA 21546/S-13

SUPPLEMENT APPROVAL

Merck Sharp & Dohme Corp.
a subsidiary of Merck & Co., Inc.
Attention: Moon Jeong Ko
Sr. Specialist, Regulatory Affairs International
1700 Rockville Pike, Suite 525
Rockville, MD 20852

Dear Ms. Ko:

Please refer to your supplemental new drug applications (sNDAs) dated September 22, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Rebetol (ribavirin), capsules and oral solution.

These Prior Approval supplemental new drug applications provide for the following changes to the Prescribing Information and Medication Guide:

- To update the Boxed Warning, WARNING AND PRECAUTIONS, Embryo-Fetal Toxicity subsection, USE IN SPECIFIC POPULATIONS, Females and Males of Reproductive Potential subsection, PATIENT COUNSELING INFORMATION and Medication Guide to extend the duration of effective contraception use in women of childbearing potential from 6 months to 9 months after last dose of Rebetol treatment.

APPROVAL & LABELING

We have completed our review of these applications, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using

the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Myung-Joo Patricia Hong, Senior Regulatory Project Manager, at (301) 796-0807 or (301) 796-1500.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antivirals
Office of Infectious Diseases
Center for Drug Evaluation and Research

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

NDA 20903/S-57

NDA 21546/S-13

Page 3

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

POONAM MISHRA
03/16/2022 02:38:51 PM
on behalf of Division Director